Twist Bioscience (TWST) investor relations material

Technology and product strategy

• Miniaturized DNA synthesis on silicon chips enables production of up to 1 million unique DNA sequences per chip, significantly increasing capacity and reducing costs.

• Product portfolio expansion has grown the serviceable addressable market from $2B in 2021 to $7B in 2026, with a target of $13B in the future.

• Focus areas include diagnostics (notably cancer and rare disease) and therapeutics, with applications in NGS, DNA synthesis, and protein solutions.

• Strategy centers on maximizing chip utilization by adding diverse, high-value applications.

Financial performance and growth outlook

• Achieved 23% revenue growth in Q3 and guided for 25% in Q4, with more than 20% annual growth expected through 2026.

• DSPS segment revenue grew 39% in Q3, with gene shipments up 56%; therapeutics revenue grew 49% year-over-year.

• Profitability milestone targeted for Q4, aiming for adjusted EBITDA break-even.

• Long-term plan to double revenue by 2031, implying mid-teens compound annual growth.

• Gross margin improved from 30% to over 50%, with a goal of reaching 60%.

AI-driven drug discovery and data services

• AI-enabled drug discovery is a major growth driver, with orders expected to grow from $25M in 2025 to $100M in 2027.

• Confidence in future growth is based on customer cohort analysis, showing pilots convert to multi-million dollar orders over time.

• Data services now command higher value, with offerings ranging from DNA to protein to binding and developability data.

• Partnerships with Anthropic and Amazon Bio Discovery highlight leadership in AI-driven protein design and wet lab validation.